Visionquest Biomedical is categorized under Research and Development Laboratories in Albuquerque, NM and active since 2005.
Visionquest Biomedical was established in 2005, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Research and Development Laboratories business, which does work in the B2B market, and is classified as a Research and Development Laboratories, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Peter Soliz at the company’s single location by writing to 7718 Quintana Drive Ne, Albuquerque, New Mexico NM 87109 or by phoning (505) 898-6229. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Visionquest Biomedical |
Contact Person: | Peter Soliz |
Address: | 7718 Quintana Drive Ne, Albuquerque, New Mexico 87109 |
Phone Number: | (505) 898-6229 |
Annual Revenue (USD): | $100.000 to $499.999 |
Founded: | 2005 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2B (Business to Business) |
Business Category: | Research and Development Laboratories |
SIC Code: | 8731 |
NAICS Code: | 541712 |
Share This Business: |
Visionquest Biomedical was started in 2005 to provide professional Research and Development Laboratories under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Peter Soliz for inquiries that concern Visionquest Biomedical by calling the company number (505) 898-6229, as your correspondence is most welcome. Additionally, the physical location of the single location of Visionquest Biomedical can be found at the coordinates 35.169355,-106.538634 as well as the street address 7718 Quintana Drive Ne in Albuquerque, New Mexico 87109.
For its online presence, you may visit Visionquest Biomedical’s website at and engage with its social media outlets through on Twitter and on Facebook.